Pricing is expected in the next 1-2 business days; the key event is the final IPO price relative to the $16-$18 range. Watch for any price revision above or below the range, as well as the underwriters' 30-day option to purchase additional shares. Strong investor interest in the non-opioid pain market could drive pricing to the high end. Post-IPO, monitor Phase 3 trial initiation and data readouts for LTG-001.
Price Chart
Executive Summary
The SEC declared effective Latigo Biotherapeutics' S-1 registration statement for its initial public offering of common stock. This clears the final regulatory hurdle for the company to price its IPO and begin trading on Nasdaq under ticker LTGO, with up to 16,000,000 shares expected to be offered in a $16-$18 range. Effectiveness is the critical milestone that unlocks the IPO pricing and proceeds, estimated at ~$247M at the midpoint, which the company needs to fund Phase 3 trials for its non-opioid Nav1.8 inhibitor LTG-001.
Key Facts
- Effectiveness occurred on August 6, 2026 for S-1 file number 333-297518
- IPO size: 16,000,000 shares of common stock
- Expected price range: $16.00 to $18.00 per share
- Net proceeds estimated at ~$247.2 million at the midpoint
- Lead candidate LTG-001 (non-opioid Nav1.8 inhibitor) has positive Phase 2 abdominoplasty data
- Company had a going concern qualification and IPO is critical to fund Phase 3 trials
- Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities are underwriters
Financial Impact
Up to ~$247.2M net proceeds at the $17 midpoint with 16M shares offered
Risk Factors
- Clinical-stage biotech with no approved products and a going concern qualification pre-IPO
- Pricing below the range or weak demand would be a negative signal
- Dilution: 16M shares plus potential greenshoe option
- Phase 3 clinical failure risk for LTG-001
- Financing risk if IPO proceeds are insufficient to complete Phase 3 development
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-002566 |
| Document: 9999999995-26-002566-index.html | 9999999995-26-002566 |
| Document: 9999999995-26-002566.txt | 9999999995-26-002566 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $23.04 $23.73 | ▲ +2.99% | ▲ +3.54% | $15.02 (−34.81%) |
Aug 12, 2026 10w ago | 3 | $19.38 $20.06 | ▲ +3.54% | ▲ +2.84% | $15.02 (−22.48%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.02 (−18.90%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.02 (−18.90%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.02 (−18.90%) |
Aug 10, 2026 11w ago | Insider Cluster | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.02 (−18.90%) |
Aug 10, 2026 11w ago | 8-K | $18.52 $19.38 | ▲ +4.62% | ▲ +4.37% | $15.02 (−18.90%) |
Aug 7, 2026 11w ago | EFFECT | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.02 (−17.70%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.02 (−17.70%) |
Aug 6, 2026 11w ago | 3 | $18.25 $18.56 | ▲ +1.70% | ▲ +1.73% | $15.02 (−17.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers